Urokinase inhibitors

Details Urokinase inhibitors Urokinase inhibitors

1998-08-06

2001-07-10

Kumar, Shailendra (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S336000, C514S426000, C514S427000, C514S429000, C514S461000, C544S330000, C546S283400, C546S284700, C548S375100, C548S557000, C548S561000, C549S480000, C549S498000

Reexamination Certificate

active

06258822

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention provides naphthamidine compounds which inhibit the urokinase enzyme, pharmaceutical compositions containing these compounds and medical methods of treatment using these compounds.
TECHNICAL FIELD
Urokinase (urinary-type plasminogen activator or uPA (International Union of Biochemistry classification number: EC3.4.21.31)) is a proteolytic enzyme which is highly specific for a single peptide bond in plasminogen. Plasminogen activation (cleavage of this bond by the urokinase enzyme) results in formation of plasmin, a potent general protease.
Many cell types use urokinase as a key initiator of plasmin-mediated proteolytic degradation or modification of extracellular support structures such as extracellular matrix (ECM) and basement membrane (BM). Cells exist, move and interact with each other in tissues and organs within the physical framework provided by ECM and BM. Movement of cells within ECM or across BM requires local proteolytic degradation or modification of the structures and allows cells to invade adjacent areas previously unavailable prior to the degredation or modification.
Cellular invasiveness intiated by urokinase is central to a variety of normal and disease-state physiological processes (Blasi, F., Vassalli, J. D., and Dano, K. J. Cell Biol. 104:801-804, 1987; Dano, K., Anderson, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Adv. Cancer Res. 44:139-266, 1985; Littlefield, B. A. Ann. N. Y. Acad. Sci. 622: 167-175, 1991; Saksela, O., Biochim. Biophys. Acta 823: 35-65, 1985; Testa, J. E. and Quigley, J. P. Cancer Metast. Rev. 9:353-367, 1990). Such processes include, but are not limited to, angiogenesis (neovascularization), bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, tissue remodelling during wound repair and organ differentiation, fibrosis, tumor invasion, metastatic spread of tumor cells from primary to secondary sites and tissue destruction in arthritis. Amiloride, for example, a known urokinase inhibitor of only moderate potency, has been reported to inhibit tumor metastasis in vivo (Kellen, J. A., Mirakian, A. Kolin, A. Anticancer Res. 8:1373-1376, 1988) and angiogenesis/capillary network formation in vitro (Alliegro, M. C. and Glaser, B. M. J. Cell Biol. 115[3 Pt 2]: 402a, 1991).
Inhibitors of urokinase, therefore, have mechanism-based anti-angiogenic, anti-arthritic, anti-inflammatory, anti-retinopathic (for anigiogenesis-dependent retinopathies), contraceptive and tumoristatic uses.
SUMMARY OF THE INVENTION
In its principle embodiment, the present invention provides a compound or a pharmaceutically acceptable salt, ester or prodrug thereof, of formula (I)
Z is selected from the group consisting of
(1) nitrogen;
(2) methine; and
(3) methine substituted with —NR
1
R
2
;
A is selected from the group consisting of
(1) hydrogen and
(2) —L
A
R
A
;
B is selected from the group consisting of
(1) hydrogen and
(2) —L
B
R
B
and
C is selected from the group consisting of
(1) hydrogen and
(2) —L
C
R
C
,
with the proviso that at least one of A, B or C is other than hydrogen; and
with the proviso that when A is other than hydrogen, at least one of B or C is other than hydrogen,
wherein for A, B, and C, L
A
, L
B
and L
C
are independently selected from the group consisting of
(1) a covalent bond,
(2) —(CH
2
)
m
—,
(3) —NR
1
—,
(4) —NR
2
C(X)NR
3
—,
(5) —C(X)—,
(6) —NR
2
C(X)—,
(7) —C(X)NR
2
—,
(8) —CH═CH—,
(9) —C≡C—,
(10) —O—,
(11) —S(O)
t
—,
(12) —C≡C(CH
2
)
n
NR
2
C(X)—,
(13) —C(X)NR
2
(CH
2
)
n
C≡C—,
(14) —(CH
2
)
n
NSO
2
—,
(15) —NR
2
SO
2
(CH
2
)
n
C≡C—,
(16) —C≡C(CH
2
)
n
NR
2
SO
2
NR
3
—,
(17) —NR
2
SO
2
NR
3
(CH
2
)
n
C≡C—,
(18) —SO
2
NR
2
—,
(19) —NR
2
SO
2
—,
(20) —NR
2
SO
2
NR
3
—,
(21) —N═N—,
(22) —C(X)N(OR
2
)—,
(23) —N(OR
2
)C(X)—,
(24) —HC═CH(CH
2
)
n
NR
2
C(X)—,
(25) —(CH
2
)
n
NR
2
C(X)CH═CH—,
(26) —CH═CH(CH
2
)
n
NSO
2
—,
(27) —NR
2
SO
2
(CH
2
)
n
CH═CH—,
(28) —(CH
2
)
n
NR
2
SO
2
NR
3
—,
(29) —NR
2
SO
2
NR
3
(CH
2
)
n
CH═CH—,
(30) —NR
2
C(O)O—,
(31) —OC(O)NR
2
—,
(32) —CH═NO—,
(33) —ON═CH— and
(34)
wherein W is selected from the group consisting of
(a) —O—,
(b) —S—,
(c) —NR
1
— and
(d) —(CH
2
)
m
—,
wherein each functional group is depicted with its tight-hand end being the end which is attached to the naphthyl or quinolyl ring and its left-hand end being the end which is attached to R
A
, R
B
or R
C
;
R
A
, R
B
and R
C
are independently selected from the group consisting of
(1) aryl;
(2) arylalkoxy, wherein the alkylene group is of one to six carbon atoms;
(3) alkyl of one to ten carbon atoms;
(4) alkenyl of two to ten carbon atoms;
(5) alkoxycarbonyl of one to six carbon atoms;
(6) alkynyl of two to ten carbon atoms;
(7) halogen;
(8) —NR
1
R
2
;
(9) heterocycle;
(10) cycloalkenyl of four to twelve carbon atoms;
(11) cycloalkyl of three to twelve carbon atoms;
(12) —NR
1
C(O)NR
2
R
3
; and
(13) —NR
1
C(O)R
50
, wherein R
50
is alkyl of one to six carbon atoms;
wherein, at each occurence, R
1
is selected from the group consisting of
(1) hydrogen;
(2) an N-protecting group;
(3) alkyl of one to six carbon atoms;
(4) alkenyl of two to six carbon atoms;
(5) alkynyl of two to six carbon atoms;
(6) aryl;
(7) arylalkyl, wherein the alkylene group is of one to six carbon atoms;
(8) cycloalkyl of three to eight carbon atoms and
(9) cycloalkylalkyl, wherein the cycloalkyl group is of three to eight carbon atoms, and the alkylene group is of one to ten carbon atoms; and
wherein, at each occurence, R
2
and R
3
are independently selected from the group consisting of
(1) hydrogen;
(2) alkyl of one to six carbon atoms;
(3) alkenyl of two to six carbon atoms;
(4) alkynyl of two to six carbon atoms;
(5) aryl;
(6) arylalkyl, wherein the alkylene group is of one to six carbon atoms
(7) cycloalkyl of three to eight carbon atoms and
(8) cycloalkylalkyl, wherein the cycloalkyl group is of three to eight carbon atoms, and the alkylene group is of one to ten carbon atoms; and
wherein, at each occurence, X is selected from the group consisting of
(1) O and
(2) S; and
wherein, at each occurence,
m is one to five,
n is zero to four and
t is zero to two; and
wherein, at each occurence, the alkyl, alkenyl, alkynyl, aryl, heterocycle, cycloalkyl, and cycloalkenyl groups are optionally substituted.
The present invention also relates to a method of inhibiting urokinase in a mammal, particularly humans, by administering a therapeutically effective amount of a composition comprising a compound of formula (I).
The present invention also relates to pharmaceutical compositions which comprise a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION
As used throughout this specification and the appended claims, the following terms have the meanings specified:
The term “alkyl,” as used herein, represents a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single hydrogen atom and is exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, neopentyl and the like and may be optionally substituted with one, two, three or four substituents independently selected from the group consisting of (1) alkoxy of one to six carbon atoms; (2) alkylsulfinyl of one to six carbon atoms; (3) alkylsulfonyl of one to six carbon atoms; (4) amino; (5) aryl; (6) arylalkoxy, wherein the alkylene group is of one to six carbon atoms; (7) aryloyl; (8) azido; (9) carboxaldehyde; (10) cycloalkyl of three to eight carbon atoms; (11) halo; (12) heterocycle; (13) (heterocycle)oxy; (14) (heterocycle)oyl; (15) hydroxy; (16) N-protected amino; (17) nitro; (18) oxo; (19) spiroalkyl of three to eight carbon atoms; (20) thioalkoxy of one to six carbon atoms; (21) —CO
2
R
2
; (22) —C(O)NR
2
R
3
; (23) —SO
2
R
4
, wherein R
4
is selected from the group consisting of (a) alkyl, (b) aryl a

Affiliated with

Also associated with

Rating

Urokinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Urokinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urokinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2488427